The Redwood Study for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
The Redwood Study - a clinical research study for adults 18 to 75 years of age who have Alpha-1 Liver Disease - is enrolling.
There is currently no approved treatment available for Alpha-1 Liver Disease. The investigational study drug, TAK-999 (fazirsiran), aims to reduce the production of the abnormal Z-AAT protein and its buildup in the liver. The reduction in levels of the protein may result in a decrease in liver scarring.
The investigational study drug being evaluated alongside the placebo, which appears similar to TAK-999 but contains no active medication, may help researchers understand whether TAK-999 can reduce liver scarring caused by Alpha-1 Liver Disease.
Who Can Participate in the Redwood Study?
- You may be eligible if you or any of your family members have confirmed or suspected diagnosis of Alpha-1 Liver Disease.
- If you are interested, our research staff can confirm a diagnosis of Alpha-1 Liver Disease, as well as other study criteria, to determine your eligibility.
Study Details
- Participation in The Redwood Study will last approximately four and a half years.
- Eligible participants will be chosen at random to receive either TAK-999 or a placebo.
- The procedures performed during the study (at no cost to participants) include liver biopsies, questionnaires, physical examinations, vital sign measurements, pulmonary function tests, and blood sample collections.
*All study participants will receive the assigned study treatment, study-related medical exams, and study-related laboratory tests at no cost. Reimbursement for travel expenses may be available. Further details about study support can be discussed with the study team.*